Currently Browsing

Product News

Aurobindo Receives FDA Approval for Prednisolone Tablets USP, 5 mg

Published: March 17, 2023

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Prednisolone Tablets USP, 5 mg. Aurobindo Pharma’s Prednisolone Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Prednisolone Tablets manufactured by Watson Laboratories Inc.

Prednisolone Tablets are indicated in the following conditions:

  • Endocrine disorders
  • Rheumatic disorders
  • Collagen diseases
  • Dermatologic diseases
  • Allergic states
  • Ophthalmic diseases
  • Respiratory diseases
  • Hematologic disorders
  • Neoplastic diseases
  • Edematous states
  • Gastrointestinal diseases
  • Nervous system
  • Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy; trichinosis with neurologic or myocardial involvement.